- Home
- STKS vs BMEA Comparison
STKS vs BMEA Comparison
Compare STKS & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STKS
- BMEA
- Stock Information
- Founded
- STKS 2004
- BMEA 2017
- Country
- STKS United States
- BMEA United States
- Employees
- STKS N/A
- BMEA N/A
- Industry
- STKS Restaurants
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- STKS Consumer Discretionary
- BMEA Health Care
- Exchange
- STKS Nasdaq
- BMEA Nasdaq
- Market Cap
- STKS 109.7M
- BMEA 114.3M
- IPO Year
- STKS N/A
- BMEA 2021
- Fundamental
- Price
- STKS $2.77
- BMEA $1.83
- Analyst Decision
- STKS Hold
- BMEA Strong Buy
- Analyst Count
- STKS 3
- BMEA 11
- Target Price
- STKS $4.50
- BMEA $16.55
- AVG Volume (30 Days)
- STKS 68.0K
- BMEA 586.1K
- Earning Date
- STKS 11-06-2025
- BMEA 10-28-2025
- Dividend Yield
- STKS N/A
- BMEA N/A
- EPS Growth
- STKS N/A
- BMEA N/A
- EPS
- STKS N/A
- BMEA N/A
- Revenue
- STKS $834,363,000.00
- BMEA N/A
- Revenue This Year
- STKS $26.58
- BMEA N/A
- Revenue Next Year
- STKS $5.37
- BMEA N/A
- P/E Ratio
- STKS N/A
- BMEA N/A
- Revenue Growth
- STKS 96.64
- BMEA N/A
- 52 Week Low
- STKS $2.37
- BMEA $1.29
- 52 Week High
- STKS $5.26
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- STKS 41.96
- BMEA 51.58
- Support Level
- STKS $2.64
- BMEA $1.79
- Resistance Level
- STKS $2.80
- BMEA $2.08
- Average True Range (ATR)
- STKS 0.12
- BMEA 0.12
- MACD
- STKS 0.04
- BMEA 0.01
- Stochastic Oscillator
- STKS 41.18
- BMEA 39.74
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.